NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Cencora Reaffirms Guidance After Limited Walgreens Volume Shift

Cencora reaffirms $17.75–$17.95 FY2026 EPS after minor Walgreens volume shift. Analysts see just 3–3.5% impact as core prime vendor deal stays intact.

Cencora Reaffirms Guidance After Limited Walgreens Volume Shift
Credit: Justin Merriman/Bloomberg
Already have an account? Sign in.
08/12/2026 · 3:19 PM
COR
/ Read more

Feed↓

Neurocrine Biosciences: Positive INGREZZA Study Results Meet Vykat XR Safety Concerns
08/12/2026 · 3:45 PM

Mixed News for Neurocrine: Strong TD Data for INGREZZA, Caution on Vykat XR

Neurocrine reports strong KINECT-PRO results for INGREZZA in tardive dyskinesia quality of life, while experts flag safety risks for Vykat XR.

/ Subscriber only
Lumentum (LITE) Beats Estimates, Hits Long-Term Target Early as Jefferies and Citi Reiterate $1,200 Buys
Featured/ 08/12/2026 · 12:50 PM

Lumentum Beats Estimates, Hits Long-Term Target Early as Jefferies and Citi Reiterate $1,200 Buys

LITE reports robust Q4, lifts guidance, and reaches long-term model early.

/ Subscriber only
Quantinuum Beats Estimates in First Public Earnings as Oracle Deal Signals Growing Quantum Demand
Featured/ 08/12/2026 · 12:31 PM

Quantinuum Beats Estimates in First Public Earnings as Oracle Deal Signals Growing Quantum Demand

Quantinuum tops estimates in first public earnings, raises 2026 outlook, and partners with Oracle to deploy Helios quantum computer in the cloud.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe